Summary of Study ST000996
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000675. The data can be accessed directly via it's Project DOI: 10.21228/M8DX19 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST000996 |
| Study Title | Non-Esterified Fatty Acids of Primary Sclerosing Cholangitis (part II) |
| Study Summary | To qualitatively and quantitatively analyze enterohepatically-circulated molecules using targeted free fatty acid concentrations of peripheral blood collected from primary sclerosing cholangitis (PSC) patients compared to normal and diseased controls. There are three groups of patients. (1) Normal donor controls (ND), (2) Patients with Primary Sclerosing Cholangitis (PSC), and (3) Disease Controls (DC) which are patients with liver disease other than PSC. |
| Institute | Mayo Clinic |
| Last Name | O'Hara |
| First Name | Steven |
| Address | 200 First St. SW, Rochester, Minnesota, 55905, USA |
| ohara.steven@mayo.edu | |
| Phone | 507-284-1006 |
| Submit Date | 2017-07-05 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | d |
| Analysis Type Detail | LC-MS |
| Release Date | 2019-07-17 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000675 |
| Project DOI: | doi: 10.21228/M8DX19 |
| Project Title: | Mayo Pilot and Feasibility: The Enterohepatic Metabolome in Primary Sclerosing Cholangitis |
| Project Summary: | Emerging in vitro and in vivo data, including work from our laboratory and clinical research group, suggest fundamental pathophysiologic mechanisms in primary sclerosing cholangitis (PSC) that are centered on the enterohepatic circulation of gut-derived molecules. Therefore, in this proposal, we will test the central hypothesis that increased pathologic enterohepatic circulation of enteric metabolites which trigger specific pro-fibroinflammatory hepatobiliary responses are centrally involved in the etiopathogenesis of primary sclerosing cholangitis (PSC). While these processes have been hypothesized to play a significant role in the initiation, progression, and adverse clinical sequelae of PSC, they have not been directly tested to date. In our proposal, we will experimentally address the nature and extent of the metabolomic profiles of portal and peripheral blood as well as bile in patients with PSC. We will perform qualitative and quantitative ultra-performance liquid chromatography/mass spectroscopy-based metabolomic analyses to determine metabolic changes in portal and peripheral plasma and bile. Through subsequent pathway analyses we intend to identify metabolic enzymes and known biochemical pathways that may be altered in PSC. We anticipate that patients with PSC will have distinct alterations in the portal venous and bile metabolomic profiles and associated signaling pathways compared to normal and disease controls; and these alterations may be amenable to pharmacologic manipulation and future therapies. |
| Institute: | Mayo Clinic |
| Last Name: | O'Hara |
| First Name: | Steven |
| Address: | 200 First St. SW, Rochester, Minnesota, 55905, USA |
| Email: | ohara.steven@mayo.edu |
| Phone: | 507-284-1006 |
Subject:
| Subject ID: | SU001035 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
| mb_sample_id | local_sample_id | Grouping |
|---|---|---|
| SA061678 | ms6722-23 | DC |
| SA061679 | ms6722-24 | DC |
| SA061680 | ms6722-25 | DC |
| SA061681 | ms6722-22 | DC |
| SA061682 | ms6722-21 | DC |
| SA061683 | ms6722-19 | DC |
| SA061684 | ms6722-20 | DC |
| SA061685 | ms6722-26 | DC |
| SA061686 | ms6722-27 | DC |
| SA061687 | ms6722-32 | DC |
| SA061688 | ms6722-33 | DC |
| SA061689 | ms6722-31 | DC |
| SA061690 | ms6722-30 | DC |
| SA061691 | ms6722-28 | DC |
| SA061692 | ms6722-29 | DC |
| SA061693 | ms6722-18 | DC |
| SA061694 | ms6722-17 | DC |
| SA061695 | ms6722-16 | DC |
| SA061696 | ms6722-1 | ND |
| SA061697 | ms6722-9 | ND |
| SA061698 | ms6722-8 | ND |
| SA061699 | ms6722-6 | ND |
| SA061700 | ms6722-4 | ND |
| SA061701 | ms6722-2 | ND |
| SA061702 | ms6722-3 | ND |
| SA061703 | ms6722-7 | ND |
| SA061704 | ms6722-5 | ND |
| SA061705 | ms6722-10 | PSC |
| SA061706 | ms6722-15 | PSC |
| SA061707 | ms6722-14 | PSC |
| SA061708 | ms6722-13 | PSC |
| SA061709 | ms6722-12 | PSC |
| SA061710 | ms6722-11 | PSC |
| Showing results 1 to 33 of 33 |
Collection:
| Collection ID: | CO001029 |
| Collection Summary: | After obtaining informed consent, portal and peripheral venous blood (4 ml of each) and bile (2 mL) was collected intraoperatively in a red-top tube by a Mayo Clinic LT surgeon. Blood was placed on ice, promptly fractionated by centrifugation, divided into 100 μL aliquots, and stored at -80°C. |
| Sample Type: | Blood (serum) |
Treatment:
| Treatment ID: | TR001049 |
| Treatment Summary: | We prospectively enrolled three groups of participants from the Mayo Clinic Liver Transplant inpatient service and outpatient clinics and have collected samples from: i) 9 patients with PSC who underwent living- donor LT, ii) 15 donors (normal controls), and iii) 20 patients with cirrhosis due to a disorder other than PSC who underwent LT (disease controls). The following inclusion and exclusion criteria were applied: Inclusion criteria 1. Adult (age>18 years). 2. PSC patient undergoing LT, healthy living donor, or other chronic liver disease patient undergoing LT. Exclusion Criteria: 1. Females who are pregnant or attempting to become pregnant. 2. Concomitant liver disease (e.g. chronic viral hepatitis in addition to PSC). 3. Acute intestinal disease (infectious enterocolitis, IBD flare) in the past 6 months. 4. Treatment with any investigational drugs within the past 6 months. 5. Use of antibiotics within the past 4 weeks. 6. Any previous organ transplant. 7. Hemodialysis. |
Sample Preparation:
| Sampleprep ID: | SP001042 |
| Sampleprep Summary: | nefa acid concentrations |
Combined analysis:
| Analysis ID | AN001625 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Agilent 1290 Infinity |
| Column | Waters Acquity BEH C18 (150 x 2.1mm,1.7um) |
| MS Type | ESI |
| MS instrument type | Triple quadrupole |
| MS instrument name | Agilent 6460 QQQ |
| Ion Mode | NEGATIVE |
| Units | uM |
Chromatography:
| Chromatography ID: | CH001143 |
| Instrument Name: | Agilent 1290 Infinity |
| Column Name: | Waters Acquity BEH C18 (150 x 2.1mm,1.7um) |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS001501 |
| Analysis ID: | AN001625 |
| Instrument Name: | Agilent 6460 QQQ |
| Instrument Type: | Triple quadrupole |
| MS Type: | ESI |
| MS Comments: | uM |
| Ion Mode: | NEGATIVE |
